Article thumbnail
Location of Repository

Development of novel vaccines for the concurrent immunisation against multiple dengue virus serotypes

By Steven Christopher Liew

Abstract

A major obstacle to the development of dengue virus (DENV) vaccines has been the need to immunise concurrently against each of the four DENV serotypes in order to avoid sensitising recipients to developing severe DENV infections. A problem already encountered with live attenuated tetravalent DENV vaccines has been the difficulty in eliciting adequate immune responses against all four DENV serotypes in human hosts. This could have been due to variations in the antigenicity and/or the replication rates of the four DENV serotypes. Non-replicating DNA vaccines avoid the issue of different replication rates. Currently, only DENV-1 and DENV-2 DNA vaccines have been evaluated. In this study, a number of DNA vaccines for each of the four DENV serotypes were developed and their immunogenicity was evaluated in outbred mice. These vaccines included DNA vaccines encoding the DENV prM-E protein genes derived from the four DENV serotypes (pVAX-DEN1, -DEN2, -DEN3 and -DEN4), and DNA vaccines encoding DENV prM and hybrid-E protein genes derived from multiple DENV serotypes. The hybrid-E protein genes were constructed by substituting either domains I and II, domain III, and/or the stem-anchor region from the E protein of one DENV serotype with the corresponding region from another DENV serotype. A number of superior DNA vaccines against each of the four DENV serotypes were identified based on their ability to elicit high titres (≥40, FFURNT50) of neutralising antibodies against the corresponding DENV in mice. The superior DNA vaccines against DENV-1 were pVAX-DEN1, pVAX-C2M2E211, pVAX-C2M2E122 and pVAX-C2M1E122. The superior DNA vaccine against DENV-2 was pVAX-C2M1E122 and the superior DNA vaccines against DENV-3 were pVAX-DEN3 and pVAX-C2M3E344. The superior DNA vaccines against DENV-4 were pVAX-C2M3E344, pVAX-C2M4E434 and pVAX-C2M4E433. Each of these DNA vaccines could provide effective protection against infection by the corresponding DENV serotypes. This is the first study to describe the development of DNA vaccines against DENV-3 and DENV-4. However, mice immunised with a tetravalent DENV DNA vaccine, composed of a DNA vaccine encoding the prM-E protein genes from each of the four DENV serotypes (pVAX-DEN1-4), elicited high titres of neutralising antibodies against DENV-1 and DENV-3 only. Nevertheless, the results from this study suggested that a tetravalent DENV DNA vaccine, composed of pVAX-DEN1, pVAX-C2M1E122, pVAX-DEN3 and pVAX-C2M4E434, may provide effective concurrent protection against infection by each of the four DENV serotypes. In addition, mice immunised with pVAX-C2M1E122, which encoded a hybrid-E protein gene derived from DENV-1 and DENV-2, elicited high titres of anti-DENV-1 and anti-DENV-2 neutralising antibodies, and mice immunised with pVAX-C2M3E344, which encoded a hybrid-E protein gene derived from DENV-3 and DENV-4, elicited high titres of anti-DENV-3 and anti-DENV-4 neutralising antibodies. This result suggested that the co-immunisation of these two hybrid-E DNA vaccines also may provide effective concurrent protection against infection by each of the four DENV serotypes. Extracellular E proteins, believed to be in the form of recombinant subviral particles (RSPs), were recovered from the tissue culture supernatant of all DNA vaccine-transfected mammalian cells by ultracentrifugation, except for cells transfected with the pVAX-C2M2E122 hybrid-E DNA vaccine. Western blotting with the monoclonal antibody 4G2 (flavivirus cross-reactive) demonstrated that the extracellular E proteins expressed by the DNA vaccines were synthesized and cleaved in a manner similar to that of native DENV E proteins. In addition, mammalian cells transfected with pVAX-DEN1, pVAX-DEN2 or pVAX-DEN3 secreted higher amounts of extracellular E proteins than cells transfected with pVAX-DEN4. The amount of extracellular E protein secreted by pVAX-DEN4-transfected cells increased when the c-region of the prM/E signal peptidase cleavage site was made more polar. In contrast, decreasing the polarity of the c-region of the C/prM signal peptidase cleavage site of pVAX-DEN4 resulted in no detectable extracellular E proteins from pVAX-DEN4-transfected cells. This result suggested that the amount of extracellular E proteins secreted by cells transfected with DNA expressing the DENV prM-E protein genes may be dependent of the efficiency of C/prM and prM/E protein cleavages by host-derived signal peptidases. Mice immunised with the mutated pVAX-DEN4, which was capable of expressing large amounts of extracellular E proteins in vitro, produced significantly higher concentrations of Th1-type anti-DENV-4 antibodies than mice immunised with the unmodified pVAX-DEN4, but failed to produce detectable levels of anti-DENV-4 neutralising antibodies. In contrast, increasing the ratio of CpG-S to CpG-N motifs in the pVAX-DEN2 DNA vaccine by incorporating either an additional CpG-S motif, or an antibiotic resistance gene with a high ratio of CpG-S to CpG-N motifs, resulted in a significant increase in both the concentration of Th1-type anti-DENV-2 antibodies and the titres of anti-DENV-2 neutralising antibodies in immunised mice. This result suggested that increasing the amount of CpG-S motifs in DENV DNA vaccines may present an simple and effective approach to increasing the immunogenicity of the DENV DNA vaccines

Topics: dengue virus, dengue vaccine, DNA vaccine, tetravalent vaccine, E protein, recombinant subviral particles, signal peptide, signal peptidases, CpG motifs, hybrid E proteins
Publisher: Queensland University of Technology
Year: 2006
OAI identifier: oai:eprints.qut.edu.au:16199

Suggested articles

Citations

  1. (1991). 17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein.
  2. (1997). A conserved internal hydrophobic domain mediates the stable membrane integration of the dengue virus capsid protein.
  3. (2000). A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
  4. (1999). A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.
  5. (2000). A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice.
  6. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein.
  7. (1994). A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
  8. (2001). A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
  9. (2003). A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
  10. (2001). A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E.
  11. (1990). A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study.
  12. (2004). A novel principle of attenuation for the development of new generation live flavivirus vaccines. Arch Virol Suppl,
  13. (2003). A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses.
  14. (2000). A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.
  15. (2000). A Toll-like receptor recognizes bacterial DNA.
  16. (1983). A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.
  17. (2003). A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.
  18. (1998). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
  19. (1991). Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.
  20. (2001). Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour.
  21. (2002). Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.
  22. (1997). Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice.
  23. (2000). Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?
  24. (2004). Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses.
  25. (2003). American genotype structures decrease dengue virus output from human monocytes and dendritic cells.
  26. (2001). Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody.
  27. (2001). Amplification and cloning of the full-length genome of Japanese encephalitis virus by a novel long RT-PCR protocol in a cosmid vector.
  28. (1987). An improved micromethod for infectivity assays and neutralization tests of dengue viruses.
  29. (2001). An infectious clone of the West Nile flavivirus.
  30. (2002). An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization.
  31. (1989). Analyses of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis.
  32. (1997). Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system.
  33. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice.
  34. (1995). Analysis of functional epitopes on the dengue 2 envelope (E) protein using monoclonal IgM antibodies.
  35. Anonymous (1997b). Re-emergence of Dengue in the Americas.
  36. (1998). Antagonism of immunostimulatory CpGoligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.
  37. (1990). Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation.
  38. (1977). Antibody-enhanced dengue virus infection in primate leukocytes.
  39. (1988). Antigen chimaeras of poliovirus as potential new vaccines.
  40. (1990). Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
  41. (1991). Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.
  42. (1999). Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.
  43. (1984). Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.
  44. (1988). Antiviral, antiglycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.
  45. (1994). Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.
  46. (2001). Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively.
  47. (2001). Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
  48. (2000). Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.
  49. (1994). Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.
  50. (2002). Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
  51. (1997). Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12.
  52. (1999). Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis.
  53. (1997). Blocking antibodies inhibit complete African swine fever virus neutralization.
  54. (1991). Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins.
  55. (1991). Breakdown of the blood-brain barrier during dengue virus infection of mice.
  56. (1999). Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic Tlymphocyte clones.
  57. (2002). Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.
  58. Case Definitions: Dengue and Leptospirosis.
  59. (1990). Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody.
  60. (1998). Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.
  61. (2001). Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine.
  62. (1999). Characterization of infectious Murray Valley encephalitis virus derived from a stably cloned genomelength cDNA.
  63. (1997). Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice.
  64. (1992). Characterization of the dengue virus-induced helper cytokine.
  65. (2004). Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
  66. (2000). Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.
  67. (1991). Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs.
  68. (1993). Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.
  69. (2000). Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
  70. (1993). Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site.
  71. (2003). Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.
  72. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  73. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
  74. (1997). Clinical spectrum of dengue infection.
  75. (1981). Cloned poliovirus complementary DNA is infectious in mammalian cells.
  76. (1991). Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus.
  77. (1994). Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned fulllength cDNA.
  78. (1993). Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus.
  79. (1987). Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences.
  80. (2000). Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain.
  81. (1997). Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.
  82. (2001). Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid.
  83. (1991). Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.
  84. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.
  85. (2001). Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow feverdengue virus tetravalent vaccine.
  86. (2001). Coupling between replication and packaging of flavivirus RNA: evidence derived from the use of DNA-based full-length cDNA clones of Kunjin virus.
  87. (1999). CpG DNA and LPS induce distinct patterns of activation in human monocytes.
  88. (1999). CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
  89. (1998). CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species.
  90. (2002). CpG motifs in bacterial DNA and their immune effects.
  91. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation.
  92. (1996). CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry.
  93. (2002). CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo.
  94. (1998). Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides.
  95. (2000). Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis.
  96. (1993). Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain.
  97. (1997). Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem.
  98. (1998). Dengue and dengue hemorrhagic fever.
  99. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control (Geneva, World Health Organization).
  100. (1990). Dengue hemorrhagic fever in Venezuela.
  101. (2000). Dengue in the Americas: The Epidemics of
  102. (2002). Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine.
  103. (1996). Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
  104. (2000). Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.
  105. (1996). Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein.
  106. (1999). Dengue virus structural differences that correlate with pathogenesis.
  107. (2000). Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.
  108. (1991). Dengue virus-induced helper cytokine has two polypeptide chains which bear different determinants.
  109. (1993). Dengue virus-specific human CD4+ Tlymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination.
  110. (1994). Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.
  111. (1995). Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.
  112. (1977). Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.
  113. (1991). Dengue virusspecific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones.
  114. (1988). Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
  115. (1987). Dengue-specific IgM and dengue haemorrhagic fever/shock [letter].
  116. (2004). Dengue: defining protective versus pathologic immunity.
  117. (1994). Dengue: the risk to developed and developing countries.
  118. (2002). Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.
  119. (1998). Development and analysis of a tick-borne encephalitis virus infectious clone using a novel and rapid strategy.
  120. (2003). Development and application of a reverse genetics system for Japanese encephalitis virus.
  121. (1996). Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.
  122. (2001). Development of new vaccines against dengue fever and Japanese encephalitis.
  123. (2001). Diagnostic immunoassays for tick-borne encephalitis virus based on recombinant baculovirus protein expression.
  124. (1997). Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization.
  125. (1992). Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiological investigations.
  126. (1992). DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth.
  127. (1998). DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice.
  128. (2003). DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus.
  129. (2002). DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.
  130. (1997). DNA vaccines -- a modern gimmick or a boon to vaccinology?
  131. (2000). DNA vaccines: development, standardization and regulation.
  132. (1997). DNA vaccines: safety and efficacy issues.
  133. (1997). DNA vaccines.
  134. (1998). DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus.
  135. (1996). Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a.
  136. (1999). Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity.
  137. (2002). Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model.
  138. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
  139. (2003). Enhancement of DNA vaccine potency against herpes simplex virus 1 by coadministration of an interleukin-18 expression plasmid as a genetic adjuvant.
  140. (2003). Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.
  141. (2001). Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies.
  142. (2001). Essential role of cyclization sequences in flavivirus RNA replication.
  143. (1989). Eukaryotic signal peptide structure/function relationships. Identification of conformational features which influence the site and efficiency of co-translational proteolytic processing by sitedirected mutagenesis of human pre(delta pro)apolipoprotein A-II.
  144. (1990). Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants.
  145. (2000). Evaluation of the potency of BIKEN inactivated Japanese Encephalitis vaccine and DNA vaccines in an intracerebral Japanese Encephalitis virus challenge [letter].
  146. (1999). Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
  147. (2003). Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice.
  148. (1995). Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum.
  149. (1988). Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.
  150. (1990). Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein.
  151. (2002). Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3.
  152. (1999). Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever.
  153. (1995). Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system.
  154. (1998). First human trial of a DNA-based vaccine for treatment of human 248 immunodeficiency virus type 1 infection: safety and host response.
  155. (2003). Flavivirus capsid is a dimeric alpha-helical protein.
  156. (1991). Flavivirus enzymesubstrate interactions studied with chimeric proteinases: identification of an intragenic locus important for substrate recognition.
  157. (1990). Flavivirus genome organization, expression, and replication.
  158. (1993). Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3.
  159. (1995). Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones.
  160. (1999). Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens.
  161. (1997). Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide.
  162. (1995). Formation of the flavivirus envelope: role of the viral NS2B-NS3 protease.
  163. (2001). Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge.
  164. (1997). Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins.
  165. (2002). Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines.
  166. (1999). Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
  167. (1988). Gene mapping and positive identification of the non-structural proteins NS2A, NS2B, NS3, NS4B and NS5 of the flavivirus Kunjin and their cleavage sites.
  168. (2001). Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.
  169. (1998). Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.
  170. (1999). Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function.
  171. (2004). Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
  172. (1998). Growth restriction of dengue virus type 2 by site-specific mutagenesis of virusencoded glycoproteins.
  173. (1995). Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome.
  174. (1994). Heterogeneity of genomes: measures and values.
  175. (1984). Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies.
  176. (1996). High levels of sTNFR p75 and TNF alpha in dengue-infected patients.
  177. (1999). Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor.
  178. (1984). How signal sequences maintain cleavage specificity.
  179. (1992). Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen.
  180. (1989). Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production.
  181. (1998). Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA.
  182. (1999). Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.
  183. (2001). Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.
  184. (1982). Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.
  185. (2001). Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies.
  186. (2001). Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.
  187. (1998). Identification of specific nucleotide sequences within the conserved 3'-SL in the dengue type 2 virus genome required for replication.
  188. (1996). Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.
  189. (1996). IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides.
  190. (1987). IgG2a restriction of murine antibodies elicited by viral infections.
  191. (2000). Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.
  192. (1996). Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.
  193. (1995). Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins.
  194. (1995). Immunization against viral proteins with naked DNA.
  195. (1988). Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis.
  196. (2000). Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
  197. (1987). Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
  198. (1999). Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies.
  199. (1996). Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells.
  200. (2000). Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.
  201. (1999). Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
  202. (1999). Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
  203. (1970). Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys.
  204. (2001). Immunological determinants on dengue virions: Is a chimeric vaccine a possibility? In Arbovirus Research
  205. (1962). Immunological studies with group B arthropod-borne viruses.II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subject following administration of 17D yellow fever vaccine.
  206. (1999). Immunopathogenesis of Dengue hemorrhagic fever.
  207. (1994). Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome.
  208. (1993). Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system.
  209. (1996). Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.
  210. (1997). Immunosuppression and cytotoxicity of dengue infection in the mouse model.
  211. (2004). Improved prediction of signal peptides:
  212. (2000). Improving DNA vaccines targeting viral infection.
  213. (1990). In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3.
  214. (2001). In vitro RNA synthesis from exogenous dengue viral RNA templates requires long range interactions between 5'- and 3'-terminal regions that influence RNA structure.
  215. (1991). In vitro synthesis of West Nile virus proteins indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids.
  216. (2004). In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine.
  217. (1998). Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates [published erratum appears in Vaccine
  218. (1996). Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
  219. (1999). Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
  220. (1998). Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.
  221. (2001). Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine.
  222. Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr.
  223. (1992). Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates.
  224. (1983). Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.
  225. (1991). Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.
  226. (1997). Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast.
  227. (1995). Infectious transcripts of tick-borne encephalitis virus, generated in days by RT-PCR.
  228. (1996). Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery.
  229. (2003). Inhibition of interferon signaling by dengue virus.
  230. (2002). Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells.
  231. (2003). Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice.
  232. (1997). Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice.
  233. (1997). Internal proteolysis of the NS3 protein specified by dengue virus 2.
  234. (2004). Introduction of mutations into the nonstructural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
  235. (2000). Invited commentary: Dengue lessons from Cuba.
  236. (1978). Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses.
  237. (2000). Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
  238. (1991). Japanese encephalitis virus-vaccinia recombinants produce particulate 249 forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection.
  239. (1997). Live attenuated tetravalent dengue vaccine.
  240. (1992). Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody.
  241. (1999). Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E.
  242. (2000). Mechanism and function of a newly identified CpG DNA motif in human primary B cells.
  243. (2003). Mechanisms for generation of immune responses.
  244. (2000). Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system.
  245. (1995). Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay.
  246. (1995). Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection.
  247. (1992). Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection.
  248. (1989). Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis.
  249. (2003). Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.
  250. (1998). Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.
  251. (2001). Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
  252. (1997). Molecular biology of dengue viruses.
  253. (2001). Molecular Cloning:
  254. (1993). Molecular epidemiology of dengue 3 viruses and genetic relatedness among dengue 3 strains isolated from patients with mild or severe form of dengue fever in French Polynesia.
  255. (1994). Molecular evolution and epidemiology of dengue-3 viruses.
  256. (1997). Molecular evolution and phylogeny of dengue-4 viruses.
  257. (2001). Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus.
  258. (1996). Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.
  259. (1989). Monoclonal antibodies for 239 dengue virus prM glycoprotein protect mice against lethal dengue infection.
  260. (1998). Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus,
  261. (1995). Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein.
  262. (2001). Mutagenesis of the Dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication.
  263. (2001). Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus.
  264. (2000). Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production.
  265. (1996). Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
  266. (2001). Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.
  267. (2003). Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.
  268. (1997). Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.
  269. (2003). Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM- 257 CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys.
  270. (1987). Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys.
  271. (1987). Neurovirulence effects of dengue-2 viruses on the rhesus (Macaca mulatta) brain and spinal cord.
  272. (1993). Neutralization of animal viruses.
  273. (1985). Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies.
  274. (1986). Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.
  275. (1994). NS2B-3 proteinase-mediated processing in the yellow fever virus structural region: in vitro and in vivo studies.
  276. (1989). Nterminal domains of putative helicases of flavi- and pestiviruses may be serine proteases.
  277. (1991). Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants.
  278. (1992). NYVAC: a highly attenuated strain of vaccinia virus.
  279. (1970). Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.
  280. (1906). On the etiology of dengue fever.
  281. (2000). Optimization strategies for DNA vaccines.
  282. (2003). Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.
  283. (1998). Overview of biological effects of addition of DNA molecules to cells.
  284. (1999). Partial agonist effect influences the CTL response to a heterologous dengue virus serotype.
  285. (1997). Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice.
  286. (1987). Pathogenesis of dengue haemorrhagic fever: towards a more balanced view.
  287. (1988). Pathogenesis of dengue: challenges to molecular biology.
  288. (1983). Patterns of amino acids near signal-sequence cleavage sites.
  289. (1994). Pervasive CpG suppression in animal mitochondrial genomes.
  290. (2003). Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
  291. (1998). Phylogeny of the genus Flavivirus.
  292. (2002). Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein.
  293. (2000). Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice.
  294. (1994). Plasmid integration, amplification and cytogenetics in CHO cells: questions and comments.
  295. (2000). Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles.
  296. (1996). Points to consider on plasmid DNA vaccines for preventive infectious disease indications (Docket no.
  297. (1995). Posttranslational signal peptidase cleavage at the flavivirus C-prM junction in vitro.
  298. (1997). Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
  299. (1996). Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.
  300. (1980). Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation.
  301. (1990). Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
  302. (1992). Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5.
  303. (1992). Processing of dengue virus type 2 structural proteins containing deletions in hydrophobic domains.
  304. (1993). Processing of the dengue virus type 2 proteins prM and C-prM.
  305. (1945). Production of immunity to dengue with virus modified by propagation in mice.
  306. (1993). Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein.
  307. (1989). Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a.
  308. (1988). Proteases involved in the processing of viral polyproteins. Brief review.
  309. (1985). Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.
  310. (1988). Protection against Japanese encephalitis by inactivated vaccines.
  311. (1999). Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes.
  312. (1986). Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.
  313. (1996). Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells.
  314. (1987). Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1.
  315. (1990). Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine.
  316. (1994). Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells.
  317. (1998). Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses.
  318. (2002). Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model.
  319. (2001). Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.
  320. (1997). Proteolytic activation of tick-borne encephalitis virus by furin.
  321. (1990). Proteolytic processing of picornaviral polyprotein.
  322. (1989). Proteolytic processing of polyproteins in the replication of RNA viruses.
  323. (2000). Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice.
  324. (1996). Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway.
  325. (1992). Recombinant alphainterferon inhibits colony formation of bone marrow fibroblast progenitor cells (CFU-F).
  326. (1995). Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis.
  327. (1991). Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice.
  328. (2000). Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
  329. (1996). Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity.
  330. (1997). Recombinant dengue virus vaccines.
  331. (2000). Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice.
  332. (1996). Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions.
  333. (1992). Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.
  334. (1985). Recombinant vaccinia virus: immunization against multiple pathogens.
  335. (1994). Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice [published erratum appears in Vaccine
  336. (1988). Reduction of yellow fever virus mouse neurovirulence by immunization with a bacterially synthesized non-structural protein (NS1) fragment.
  337. (1993). Regulation of the late events in flavivirus protein processing and maturation.
  338. (1994). Regulatory considerations for nucleic acid vaccines.
  339. (2000). Relative potency of cellular and humoral immune responses induced by DNA vaccination.
  340. (2001). Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein.
  341. (1985). Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication.
  342. (1952). Research on dengue during World War II.
  343. (1993). RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria.
  344. (2004). Role of CD8+ T cells in control of West Nile virus infection.
  345. (2001). Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus.
  346. (2004). Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
  347. (2004). Safety and immunogenicity of a three dose regimen of two tetravalent liveattenuated dengue vaccines in five- to twelve-year-old Thai children.
  348. (2001). Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
  349. (2000). Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vacciniaimmune humans.
  350. (2002). Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
  351. (1994). Safety considerations for nucleic acid vaccines.
  352. (1999). Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.
  353. (1999). Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines.
  354. (2005). Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein.
  355. (1994). Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence.
  356. (1998). Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.
  357. (1988). Sequence of the structural proteins of tick-borne encephalitis virus (western subtype) and comparative analysis with other flaviviruses.
  358. (1999). Sequential production of cytokines by dengue virus-infected human peripheral blood leukocyte cultures.
  359. (1993). Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients.
  360. (2001). Shed' furin: mapping of the cleavage determinants and identification of its C-terminus.
  361. (2001). Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.
  362. (1998). Signal peptidase cleavage at the flavivirus CprM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM.
  363. (1985). Signal sequences. The limits of variation.
  364. (1985). Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization.
  365. (1992). Single amino acid substitutions can convert the uncleaved signal- 235 anchor of sucrase-isomaltase to a cleaved signal sequence.
  366. (2004). Solution structure of dengue virus capsid protein reveals another fold.
  367. (2003). Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C.
  368. (1996). Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus.
  369. (2004). Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.
  370. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.
  371. (2004). Structure of the dengue virus envelope protein after membrane fusion.
  372. (2000). Structures and mechanisms in flavivirus fusion.
  373. (2003). Structures of immature flavivirus particles.
  374. (2003). studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.
  375. (1944). Studies on dengue: anti-dengue active immunisation experiments in mice.
  376. (1983). Studies on transformation of Escherichia coli with plasmids.
  377. (1978). Subclass restriction of murine anti-carbohydrate antibodies.
  378. (2003). Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
  379. (2001). Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid.
  380. (2001). Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
  381. (1995). Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain).
  382. (1995). Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form.
  383. (1989). Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody.
  384. (2002). T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity.
  385. (1997). Taxonomy and evolutionary relationships of flaviviruses.
  386. (1996). Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.
  387. (1999). The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.
  388. (1990). The dengue viruses.
  389. (1937). The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus.
  390. (1977). The emperor's new clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever.
  391. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.
  392. (1999). The first major outbreak of dengue hemorrhagic fever in Delhi,
  393. (1994). The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants.
  394. (1984). The impact of new technologies on vaccine development.
  395. (2001). The machinery for flavivirus fusion with host cell membranes.
  396. (1973). The potential pathogenic role of complement in dengue hemorrhagic shock syndrome.
  397. (1997). The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris.
  398. (1975). The relative resistance of dengue-immune monkeys to yellow fever virus.
  399. (2004). The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core.
  400. (2003). The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.
  401. (1999). The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids.
  402. (1937). The use of yellow fever virus modified by in vitro cultivation for human immunization.
  403. (2000). The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines.
  404. (2001). Tickborne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
  405. (1996). Toward the development of DNA vaccines.
  406. (2003). Traditional and novel approaches to flavivirus vaccines.
  407. (1999). transComplementation analysis of the flavivirus Kunjin ns5 gene reveals an essential role for translation of its N-terminal half in RNA replication.
  408. (1998). transComplementation of flavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK cells.
  409. (1989). Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.
  410. (1988). Transformation of bacteria with plasmid DNA by electroporation.
  411. (1992). Transport of proteins across the endoplasmic reticulum membrane.
  412. (1993). Tumor necrosis factor, other cytokines and disease.
  413. (1997). Unmethylated CpG motifs protect murine B lymphocytes against Fas-mediated apoptosis.
  414. (1997). Upregulation of signalase processing and induction of prM-E secretion by the flavivirus NS2B-NS3 protease: roles of protease components.
  415. (2003). Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
  416. (2003). Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
  417. (2004). Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
  418. (1997). Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting.
  419. (1994). vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
  420. (1984). Vaccinology of poliomyelitis.
  421. (1999). Variation in virulence of dengue virus.
  422. (1997). Vascular leak syndrome: a side effect of immunotherapy.
  423. (1981). Viral epitopes and monoclonal antibodies: isolation of blocking antibodies that inhibit virus neutralization.
  424. (1988). Viral proteinases.
  425. (2002). Viremia and immunogenicity in nonhuman primates of a tetravalent yellow feverdengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
  426. (2003). virus as a chimeric carrier for tetravalent dengue vaccine development.
  427. (1998). Virus-encoded proteinases of the Flaviviridae.
  428. (2003). Visualization of membrane protein domains by cryo-electron microscopy of dengue virus.
  429. (2004). West Nile virus core protein; tetramer structure and ribbon formation.
  430. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.
  431. (2002). West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.
  432. (1998). WHO guidelines for assuring the quality of DNA vaccines.
  433. (1994). Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses?
  434. (2001). Yellow fever vector live-virus vaccines: West Nile virus vaccine development.
  435. (1999). Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.